Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose for acute isovolemic anemia after reverse total shoulder arthroplasty
KCT0004020Phase 4Terminated
- Sponsor
- Exactech
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferric carboxymaltose in anaemia, glenohumeral osteoarthritis, Rotator cuff deficiency (RCD), rotator cuff arthropathy (CTA), sponsored by Exactech. Started Jul 2019; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemiaglenohumeral osteoarthritisRotator cuff deficiency (RCD)rotator cuff arthropathy (CTA)
Beyond the preview
Go deeper on KCT0004020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004020.